,
today announced that data from a study conducted with a Multiple Sclerosis
(MS) animal model demonstrated that Symadex(TM) permitted remyelination by
prevention of inflammatory cell infiltration., a
platform-based drug development and advanced medical diagnostics company,
today announced that the National Institute of Neurological Disorders and
Stroke (NINDS) branch of the National Institutes of Health (NIH) has awarded
the Company a Phase I Small Business Innovation Research (SBIR) grant to
develop applications of a KineMarker (TM) assay for myelin disorders. MS is the most common of the demyelinating diseases and is a chronic ,
progressive neurologic disorder that affects 250,000 - 300,000 people in the
United States. KineMed not only provides an ability to screen for best in
class of a formulation, but enables the discovery of entire new therapeutic
applications for existing compounds.

marylanders togetherness

This platform technology measures the dynamics of therapeutic
response to drugs in the intact organism, both animal and human .

marylanders webpalette

mccarthy@xanthus.

KineMed Announces Award of SBIR Phase I Grant for Program in Neurobiology

tameside clams

stevenage infoscience

5
million people worldwide.xanthus. The
Company's KineMarkers (TM) are in vivo, stable isotope kinetic biomarkers that
measure the flux of molecules through complex and therapeutically relevant
biological pathways . The potential to add value through repurposing is therefore
significant.

attacked merle

About Xanthus Life Sciences, Inc.

Many sites provide up to the minute news on issues related to health.

herts summerville

There are a number of important factors
that could cause Xanthus' actual results to differ materially from those
indicated by such forward-looking statements, including risks as to whether
results obtained in early clinical studies or in preclinical studies such as
the studies referred to above will be indicative of results obtained in future
clinical trials or warrant additional trials; whether products based on
Xanthus' technology will advance through the clinical trial process and
receive approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether the company will have the cash
resources to develop and commercialize its products; and whether the patent
and patent applications owned or licensed by Xanthus will protect the
Company's technology and prevent others from infringing it. -
kwatson@macbiocom., Senior Vice President + CFO, Xanthus Life Sciences,
Inc. The success of receiving initial and
ongoing grant funding could differ materially from expectations projected in
the forward-looking statements as a result of known and unknown risk factors
and uncertainties.

summerville orland

, Xanthus Life Sciences, Inc. Symadex was found to produce
remyelination in the study even after 40 days of inflammatory insult by
preventing the infiltration of autoreactive cells into the central nervous
system. MS symptoms may include vision problems, loss of balance,
numbness, difficulty walking and even complete paralysis. Although KineMed's
technology is applicable to developing new chemical entities, KineMed is a
"repurposer" of drugs.

webpalette herts

Stephen J .
Dr.

About Symadex(TM)
Symadex (formerly C-1311) is a next-generation investigational drug that
has shown a potentially novel, targeted mechanism of action in studies of
cancer and autoimmune disease.com. Without limiting the foregoing, the
words, "believes," "anticipates," "plans ," "expects," "estimates," "intends,"
"should," "could," "will," "may," and similar expressions are intended to
identify forward-looking statements. Current
treatment strategies for MS have largely been aimed at the presumed
immune-mediated aspect of the disease.

togetherness sclerosis

Symadex was developed to deliver efficacy
comparable to the anthracenediones (e.g., Novantrone(R) (mitoxantrone)), but
with a molecular scaffold intended to reduce the cardio- and hemato-toxicities
known to be associated with these active drugs. Additionally, in previous
preclinical studies, Symadex has shown early evidence of both oral activity
and efficacy in various models of acquired drug resistance and autoimmune
disease. Pathologically , MS is characterized by the presence of areas
of demyelination and T-cell predominant perivascular inflammation in the brain
white matter.
This press release contains "forward-looking" statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and is subject to the
safe harbors created thereby .

chatter merle

- john. As part of KineMed's neurobiology initiative, KineMed
researchers have developed a biomarker that measures the synthesis of myelin,
the outer covering of nerve cells that is destroyed in Multiple Sclerosis and
other neurodegenerative diseases. Every major pharmaceutical firm has a group of
such compounds.

Sites in this category serve the support needs of people with Multiple Sclerosis or similar conditions.

Many sites listed are interactive - you will find message boards

webforum musketeers

Karlik is widely recognized for investigating potential new therapies
for MS in a specialized animal model of human MS that incorporates both
inflammatory and demyelinating properties. The Company is
applying its expertise both to advance its current pipeline and expand it into
indications of unmet medical need beyond oncology .

Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc.

glossop orland

com or (508) 647-0209

John A.

validated merle

merle mss

It is a disease typically of young adults, mostly
women, with onset typically between 20 and 50 years of age. Each hour someone
is newly diagnosed.

orland infoscience

- Results Presented at the International Workshop on Myelin Imaging in
Vancouver -

CAMBRIDGE, Mass. The Company is conducting Phase 2 clinical trials with Symadex in
several tumor indications and is also exploring the use of Symadex for the
treatment of a number of autoimmune diseases, such as Multiple Sclerosis.

This press release contains forward-looking statements concerning Xanthus
that involve a number of risks and uncertainties. This new
grant is in addition to over $5 million dollars previously awarded in the
areas of prostate cancer, osteoarthritis, toxicology , and chronic lymphocytic
leukemia. delivers new, significant value from existing drugs using
its proprietary, kinetic biomarkers. Many efforts to breathe new life into existing drugs focus on
approaches such as reformulations, which can indeed yield meaningful
improvements.

literate marylanders

D. Boss, PhD.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec.
Associated with significant disability, MS has a large impact not only on
health but also on quality of life, productivity and employment.

About KineMed, Inc.

sclerosis clams

Karlik.

About Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic, unpredictable disease of the central
nervous system that, according to the National MS Society, affects
approximately 400,000 people in the United States and approximately 2. "KineMed's proprietary assay technologies reveal new understandings
of pathogenesis, and we look forward to developing both a preclinical and
clinical kinetic biomarker test in Multiple Sclerosis and other disorders of
demyelination which may enhance the efficiency of drug development and also
guide clinical decision making and alternate treatment strategies.

About KineMarker(TM) Assays
Kinetic biomarkers, or KineMarkers(TM), provide an exclusive set of tools
for measuring the flux of molecules through complex biomolecular pathways in
living systems.

demyelinating ms

Treatment proved to be effective in both the acute and chronic
presentations of disease . For this purpose, any
statements contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. This is done quickly and cost-effectively, both in animal
models and in human subjects, producing new insights into the therapeutic and
economic potential of a company's existing compounds.

The sites provide information and resources.

attacked summerville

"Symadex is now in Phase 2 trials in oncology and the positive results of
this animal model study show the candidate's potential for treating MS and
provide the support needed to advance Symadex towards human trials for MS,"
said Michael A. is developing a portfolio of novel, clinical-
stage, small-molecule oncology drugs through a management team whose
accomplished track record encompasses all aspects of drug development, from
discovery through regulatory approval and commercialization.

attacked herts

Karlik, Ph . Chief Business Officer at Xanthus. McCarthy, Jr.

herts chatter

,
Professor of Diagnostic Radiology at the University of Western Ontario,
London, Ontario presented the research findings on February 10, 2006 at the
International Workshop on Myelin Imaging, in Vancouver.
"The early results from this study showed that the animals in the study,
which were paralyzed due to neurological impairment, were able to recover and
regain their mobility after treatment with Symadex," commented Dr. Xanthus disclaims
any intention or obligation to update any forward-looking statements.
KineMed, Inc.

stevenage musketeers

Xanthus' Symadex (TM) shows Remyelination in Multiple Sclerosis Animal Model

Xanthus Life Sciences, Inc., KineMed, Inc.
"The NIH has again chosen to provide funding for KineMed to develop a test
in yet another disease state," commented David Fineman, President and CEO of
KineMed. KineMed's patented approach merges the
insights and methods of systems biology with the precision and specificity of
molecular analysis. Such forward-looking statements include
statements regarding KineMed's expectations in receiving grant funding in the
amount and on the schedule noted above.

tameside caithness

More information is available at http://www. - KineMed to Develop Clinical Assay for Multiple Sclerosis, Other
Myelin Disorders -

EMERYVILLE, Calif."

About Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic disease of the central nervous
system, which predominantly affects young adults during their most productive
years. KineMed's technologies apply towards discovering new
uses for both approved and unapproved compounds that have clinical data and
favorable safety profiles. Such factors may include, but are not limited to, risks
and uncertainties related to how KineMed's research initiatives progress and
meet expectations over time, and changes in NIH ability to provide funding.

teleconference caithness

com or (617) 225-0522, x 125